

North Central Cancer Treatment Group

N0177: Pilot and Phase II Trial of OSI-774 and Radiation in Glioblastoma Multiforme Patients

Revised Status Change – October 23, 2003

NOTICE OF STATUS CHANGE

Note: An incorrect effective date was reflected on the previous Status Change Notice (November 14, 2003). This has now been corrected.

Study 2 will reopen to Mayo Rochester, Jacksonville, Scottsdale and the University of Alabama at Birmingham effective Friday, October 23, 2003, for accrual of 3 patients at dose level 3B (200 mg).

Please retain this notice with the protocol.